Sept 3, 2020 – Evolva is pleased to announce that the findings on cognition, cerebrovascular function and cardiometabolic markers in postmenopausal women from the RESHAW (Resveratrol Supporting Healthy Aging in Women) clinical study have been peer-reviewed and published in Clinical Nutrition. The report, “Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: a 24-month randomised, controlled, crossover study,” is the third in the series of anticipated publications from the extensive two-year RESHAW clinical trial of Veri-te™ resveratrol.
Conducted in Australia by Ph.D. candidate Jay Jay Thaung Zaw, Emeritus Professor Peter Howe, and Dr. Rachel Wong at the University of Newcastle’s Clinical Nutrition Research Centre, Australia, RESHAW is the largest, longest-running study of its kind with resveratrol. The first two peer-reviewed publications from the RESHAW study have reported the cerebrovascular and cognitive benefits, as well as bone mineral density improvements in 125 postmenopausal women. A wide range of secondary outcomes, including perceptions of wellbeing, quality of life, mood, physical function, and pain are expected to be published soon.
In the crossover comparison, a wide range of cognitive tests measuring several cognitive domains were performed at 12-month intervals. “Upon reviewing the Z-scores for all the cognitive domains, there was a significant 33% improvement in overall cognitive performance attributed to resveratrol supplementation compared to the placebo,” commented NHMRC-ARC Dementia Research Fellow Dr. Wong. They also observed a “12% improvement in cerebrovascular responsiveness (CVR) to hypercapnia and overall neurovascular coupling was enhanced by 7% with resveratrol,” adds Dr. Wong.
Within the same study, “a subgroup analysis showed that improvements of verbal memory with resveratrol supplementation were greater in women over 65 than in younger women,” adds Professor Peter Howe.
“What’s really powerful about these results is that the researchers also reported that 88% of the women stated that they would be likely to continue with resveratrol supplementation after the conclusion of the study” said Clare Panchoo, VP, Health Ingredients, Evolva. Furthermore, “the RESHAW exit survey details that more than half the women in the study reported that their perceived memory, mood and other aspects of living were improved with the supplementation,” adds Panchoo. “We can foresee that these significant health outcomes observed in postmenopausal women, after supplementation of 75 mg of resveratrol twice a day, will be quickly translated into new product development and ultimately fulfill the gap in this underserved market segment,” said Panchoo.
– ends –
About Veri-te™ resveratrol
Veri-teTM resveratrol offers customers a guarantee of quality together with strong scientific backing and versatility in application, which can both inspire and enable customers to develop innovative and award-winning products. www.veriteresveratrol.com
Evolva is a Swiss biotech company focused on the research, development and commercialization of products based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees are dedicated to producing the best ingredients that can contribute to health, wellbeing and sensory enjoyment. Find out more at www.evolva.com.
Veri-te Contact Details
+41 61 485 20 00